Spectrum Pharmaceuticals, Inc. is a biotechnology company engaged in acquiring, developing, and marketing prescription drug products for hematology and oncology. The company’s oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. For more information, visit the company’s website at www.sppirx.com.